| |
|
|
|
Cambridge Healthtech Institute, Boston, MA
2015-08-24
Cambridge Healthtech Institute is pleased to bring you the Tenth Annual ImVacS: Immunotherapy and Vaccine Summit. From its beginnings as a lone adjuvants conference, ImVacS has grown to a multi-track event spanning vaccines, immunotherapies, and platform technologies. This year's event has been expanded to five days with coverage on adjuvants, vaccine and immunotherapy technologies, immunomodulatory therapeutic antibodies for cancer, combination cancer immunotherapy, and T cell target discovery. ImVacS 2015 promises to be a must-attend event for commercial and academic entities to continue advancing immunotherapies and vaccines through technology and innovation.
|
|
|
|
|
|
|
|
Organized by:
|
|
Cambridge Healthtech Institute |
|
|
Invited Speakers:
|
|
- Michael C. Jensen, M.D., Janet & Jim Sinegal Endowed Professor, Pediatrics; Adjunct Professor, Bioengineering, University of Washington School of Medicine; Joint Member, Program in Immunology, Fred Hutchinson Cancer Research Center
- Rodger Novak, M.D., Ph.D., CEO & Founder, CRISPR Therapeutics Within less than two years after its inception the CRISPR-Cas
- Nathalie Garçon, Ph.D., Pharm.D., CSO, Bioaster
- Llew Keltner, M.D., Ph.D., CEO, EPISTAT
- Derek O’Hagan, Ph.D., Global Head, Vaccine Chemistry and Formulation Research, Novartis Vaccines
- Michael B. Atkins, M.D., Deputy Director, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2015-07-08
|
|
|
|
|
|
|
|
Registration:
|
|
For more information or to register, visit: http://www.imvacs.com/
|
|
|
|
|
|
|
|
|